Some longtime advocates of the therapy say they’re pessimistic about its future. This is a Kaiser Health News story. Six months after it was controversially hailed by Trump administration officials as ...

The FDA’s withdrawal of its authorization for Evusheld, a monoclonal antibody therapy used to prevent and treat Covid-19, leaves no monoclonals available for this purpose. Another monoclonal, ...

Virginia Commonwealth University Medical Center has been approved under Mayo Clinic’s Expanded Access Program to administer antibody-rich convalescent plasma for the treatment of COVID-19. There is ...

On Sunday, Aug. 23, the U.S. Food and Drug Administration announced an emergency use authorization of convalescent plasma therapy to help treat COVID-19. An emergency use authorization from the FDA ...

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...

A recent study co-authored by a Warren Alpert Medical School professor showed the effectiveness of convalescent plasma therapies for treating COVID-19 early in its disease course and preventing ...

Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...

“Today I'm donating convalescent plasma,” Judy Lutkin said. “This will be my third time donating.” Lutkin had COVID-19 back in April. “I was pretty sick for about four or five days,” she said. Now she ...

WASHINGTON - The final results of a clinical trial show convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, the National Institutes of Health ...

Infusing blood plasma from people who have recovered from COVID-19 into sick patients looks good on paper. But studies of the treatment haven't... Convalescent Plasma Strikes Out As COVID-19 Treatment ...

High-titre convalescent plasma therapy given within a week of symptom onset reduced hospitalisation and death and was well tolerated in immunocompromised patients with mild COVID-19. This randomised ...

A new analysis shows how convalescent plasma can be used to prevent hospitalizations and ultimately save lives, both for COVID-19 and for the next viral pandemic that inevitably arrives. Three years ...